PacBio Hints at Low-Cost Future Instruments; Aims to Capture 10 Percent of NGS Market

"Over time, there is no reason why we can't build an instrument that costs $50,000, $100,000, $300,000, so we have got a tremendous portfolio opportunity ahead of us over time," a PacBio official said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.